Pharmaceuticals, Biotechnology and Life Sciences
Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization.
@Boehringer has the first FDA-approved therapy to slow the rate of decline in pulmonary function for systemic sclerosis-associated interstitial lung disease
Boehringer Ingelheim today announced results from two paediatric studies of dabigatran etexilate, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.
Boehringer Ingelheim’s the trial did not meet its primary endpoint, which was to show aclinically significant difference between dabigatran etexilate and ASAon reducing the risk of a recurrent stroke among post-stroke patientswith ESUS.
Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes…
New molecular platform to access intracellular targets across a broad range of tumor cell types Opens up new range of…
Boehringer Ingelheim and Eli Lilly released the positive top-line results from the trial, which evaluated the impact of treatment with…
Boehringer Ingelheim and Eli Lilly have shown consistent effects for Jardiance versus placebo on renal outcomes in patients with established…
Boehringer Ingelheim’s study showed that dose adjustment with Gilotrif helped improve patient tolerability while maintaining treatment efficacy and reduced the frequency…
Boehringer Ingelheim and HealthPrize Technologies are expanding the RespiPoints digital support program to anyone taking one of several Boehringer Ingelheim…